Wnt5
Wnt5a is a noncanonical Wnt ligand that controls tissue morphogenesis through Wnt5a-Ror-Dishevelled signaling[1]. Mechanistically, Wnt gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2, linking Wnt5a signaling to directional tissue organization[2]. Wnt5a also uses CD146 as a receptor to regulate cell migration and zebrafish embryonic convergent extension[3]. In disease models, Wnt5a signaling directly affects metastatic melanoma cell motility and invasion, supporting its use in cancer invasion studies[4]. Compared with related WNT5A isoforms, WNT5A-long inhibits proliferation, whereas WNT5A-short increases proliferation in cancer models[5]. Compared with Wnt5b, Wnt5a coordinates chondrocyte proliferation and differentiation through distinct regulation of cyclin D1 and p130 expression[6]. For experimental applications, Box5, a Wnt5a-derived hexapeptide, antagonizes Wnt5a-dependent melanoma cell migration and invasion by inhibiting Wnt5a-induced PKC and Ca2+ signaling[7].
References:
- [1]. Ho HY, et al. Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4044-51. [Content Brief]
- [2]. From the American Association of Neurological Surgeons (AANS), et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018 Aug;13(6):612-632. [Content Brief]
- [3]. Ye Z, et al. Wnt5a uses CD146 as a receptor to regulate cell motility and convergent extension. Nat Commun. 2013;4:2803. [Content Brief]
- [4]. Weeraratna AT, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002 Apr;1(3):279-88. [Content Brief]
- [5]. Bauer M, et al. WNT5A encodes two isoforms with distinct functions in cancers. PLoS One. 2013 Nov 18;8(11):e80526. [Content Brief]
- [6]. Yang Y, et al. Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development. 2003 Mar;130(5):1003-15. [Content Brief]
- [7]. Jenei V, et al. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19473-8. [Content Brief]
-
Wnt5 Related Products (10)
Related Products (10)
-
Sapanisertib
0 ImagesSynonyms: INK-128; MLN0128; TAK-228Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies.
-
Zilovertamab
0 ImagesSynonyms: UC-961; Cirmtuzumab
-
Foxy-5
0 ImagesFoxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
-
Box5 TFA
0 ImagesCat. No.: HY-123071APurity: 99.50%
-
Foxy-5 TFA
0 ImagesCat. No.: HY-P1416APurity: 99.17%Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
-
γ-Glutamylvaline
0 Imagesγ‑Glutamylvaline (γ-Glu-Val) is a calcium‑sensing receptor (CaSR) agonist. γ‑Glutamylvaline activates CaSR and facilitates its binding to β‑arrestin 2 to modulate inflammatory and metabolic homeostasis signaling. γ‑Glutamylvaline inhibits TNF‑α‑induced IL‑6/MCP‑1 and enhances adiponectin/PPARγ in adipocytes. γ‑Glutamylvaline upregulates Wnt5a, restores β‑catenin phosphorylation, and reduces serine‑phosphorylated IRS‑1 in adipocytes. γ-Glutamylvaline can be used for the research of low-grade chronic inflammation.
-
Sapanisertib (Standard)
0 ImagesSynonyms: INK-128 (Standard); MLN0128 (Standard); TAK-228 (Standard)Sapanisertib (INK-128; MLN0128; TAK-228) Standard is the analytical standard of Sapanisertib (HY-13328). This product is intended for research and analytical applications. Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies.
-
MDGCEL
0 ImagesCat. No.: HY-P5171CAS No.: 881188-48-3MDGCEL is a WNT5A peptide, that acts as a WNT5A mimicks and exhibits WNT5A antagonistic activity.
-
Sapanisertib phosphate
0 ImagesCat. No.: HY-13328ACAS No.: 1422006-47-0Synonyms: INK-128 phosphate; MLN0128 phosphate; TAK-228 phosphateSapanisertib (INK-128; MLN0128; TAK-228) phosphate is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib phosphate directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib phosphate is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies.
